Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine

• US 7,071,173 B2
• Filed: 08/12/2005
• Issued: 07/04/2006
• Est. Priority Date: 02/13/1998
• Status: Expired due to Fees

• Current Assignee: Medivir AB
• Original Assignee: Medivir AB
• Inventors: Zhou, Xiao-Xiong, Wahling, Horst
• Primary Examiner(s): Wilson, James O.
• Assistant Examiner(s): McIntosh, III, Traviss C.
• Application Number:
  US11/202,682
• Publication Number:
  US 20060058259A1
• Time in Patent Office: 326 Days
• Field of Search: 536/22.1, 536/27.1, 536/27.13, 536/27.14, 536/27.2, 514/45
• US Class Current: 514/45
• CPC Class Codes: C07C 271/22 to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
• CPC Class Codes: C07D 213/80 in position 3
• CPC Class Codes: C07D 213/85 in position 3
• CPC Class Codes: C07D 307/68 Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• CPC Class Codes: C07D 473/32 Nitrogen atom
• CPC Class Codes: C07D 513/04 Ortho-condensed systems
• CPC Class Codes: C07F 9/4006 Esters of acyclic acids which can have further substituents on alkyl
• CPC Class Codes: C07F 9/404 containing hydroxy substituents in the hydrocarbon radicals
• CPC Class Codes: C07F 9/4075 Esters with hydroxyalkyl compounds
• CPC Class Codes: C07F 9/572 Five-membered rings
• CPC Class Codes: C07H 17/08 Hetero rings containing eight or more ring members, e.g. erythromycins
• CPC Class Codes: C07H 19/00 Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
• CPC Class Codes: C07H 19/16 Purine radicals
• CPC Class Codes: C40B 40/00 Libraries per se, e.g. arrays, mixtures

Abstract

A method for treatment of HBV and HIV infections comprising administering the compound or salt of formula Ig

Claims

1. A compound of the formula

2. A compound according to claim 1, wherein both R₂ are the residues of identical aliphatic L-amino acids.

3. A compound according to claim 2, wherein the L-amino acids are both L-valyl or both L-isoleucyl.

4. A compound according to claim 3, wherein the compound is denoted

5′

-O-[(R) 2,3-bis-(L-(valyloxy)-propionyl]-2′

,3′

-dideoxy-3′

-fluoroguanosine;

5′

-O-[(R) 2,3-bis-(L-(isleucyloxy)-propionyl]-2′

,3′

-dideoxy -3′

-fluoroguanosine;

5′

-O-[(SR) 2,3-bis-(L-(valyloxy)-propionyl]-2′

,3′

-dideoxy-3′

-fluoroguanosine;

or

5′

-O-[(SR) 2,3-bis-(L-(valyloxy)-propionyl]-2′

,3′

-dideoxy-3′

-fluoroguanosine,

or a pharmaceutically acceptable salt thereof.

5. A compound according to claim 4, denoted 5′

-O-[(R) 2,3-bis-(L-(valyloxy)-propionyl]-2′

,3′

-dideoxy -3′

-fluoroguanosine, or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier or diluent therefor.

7. A method for the treatment of HIV comprising the administration of an effective amount of a compound as defined in claim 1 to a patient infected with HIV.

8. A method for the treatment of HIV comprising the administration of an effective amount of a compound as defined in claim 5 to a patient infected with HIV.